TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $26.86.
Several equities research analysts recently commented on TGTX shares. BidaskClub lowered TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Thursday, July 13th. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd.
COPYRIGHT VIOLATION NOTICE: “TG Therapeutics, Inc. (TGTX) Receives Average Recommendation of “Buy” from Analysts” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/27/tg-therapeutics-inc-tgtx-receives-average-recommendation-of-buy-from-analysts-2.html.
Large investors have recently made changes to their positions in the business. Legal & General Group Plc boosted its holdings in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares in the last quarter. Hollencrest Securities LLC bought a new position in TG Therapeutics in the second quarter worth approximately $121,000. Bank of America Corp DE boosted its holdings in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 1,395 shares in the last quarter. UBS Group AG boosted its holdings in TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 3,736 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in TG Therapeutics in the first quarter worth approximately $170,000. Institutional investors and hedge funds own 49.86% of the company’s stock.
TG Therapeutics (NASDAQ TGTX) traded down 5.64% during trading on Wednesday, hitting $7.95. The stock had a trading volume of 4,312,170 shares. The firm’s market capitalization is $495.36 million. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35. The stock has a 50 day moving average of $11.66 and a 200 day moving average of $11.27.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. Equities research analysts expect that TG Therapeutics will post ($1.84) earnings per share for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.